Prof. Dr. DUYGU GEZEN AK

Yayın Ağı

Makaleler 9

1. The CSF Levels of Mitochondrial Phosphoenolpyruvate Carboxykinase 2 as a Novel Biomarker in Alzheimer's Disease.

İlhan N., Şahin E., Ildız S., Samancı B., Sordu P., Alaylıoğlu M., et al.

Molecular neurobiology , cilt.63, sa.1, ss.98, 2025 (SCI-Expanded, Scopus)

2. Characterization of tRNA-derived fragments in the small neuron-derived extracellular vesicles of Alzheimer's disease patients

Arioz B. I., Binokay L., Tastan B., Genc B., Cotuk A., DURSUN E., et al.

Brain Research , cilt.1862, 2025 (SCI-Expanded, Scopus)

3. Unravelling the plasma proteome: Pioneering biomarkers for differential dementia diagnosis

Gezegen H., ALAYLIOĞLU M., Şahin E., Swann O., Veleva E., Güven G., et al.

Alzheimer's and Dementia , cilt.21, sa.7, 2025 (SCI-Expanded, Scopus)

4. Clinical use and reporting of neurofilament quantification in neurological disorders: A global overview

Delaby C., Ladang A., Martinez-Yriarte J., Zecca C., Logroscino G., Körtvelyessy P., et al.

Alzheimer's and Dementia , cilt.21, sa.6, 2025 (SCI-Expanded, Scopus)

5. Association of glycoprotein 1b and miR-26a-5p levels with platelet function in Alzheimer's disease

Ayaz G., SORDU DELİBALTA P., KÜÇÜKSEZER U. C., HANAĞASI H. A., ALAYLIOĞLU M., GÜRVİT İ. H., et al.

JOURNAL OF ALZHEIMERS DISEASE , cilt.105, sa.1, ss.172-185, 2025 (SCI-Expanded, Scopus)

6. Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's disease, mild cognitive impairment, and frontotemporal dementia.

Sordu P., Alaylıoğlu M., Samancı B., Bulu E., Güleç Z. E. K., Bilgiç B., et al.

Journal of Alzheimer's disease : JAD , 2025 (SCI-Expanded, Scopus)

7. Serum and Saliva Biomolecules in Periodontitis Patients with and without Alzheimer's Disease

ÖZTÜRK D., MİDİ İ., ALAYLIOĞLU M., Tuncer E., GEZEN AK D., DURSUN E., et al.

Nigerian Journal of Clinical Practice , cilt.28, sa.3, ss.409-416, 2025 (SCI-Expanded, Scopus)

8. Glia derived neurotrophic factor: Its regulation by vitamin D and possible relation to neurodegeneration

ULUTİN A. N. T., GEZEN AK D., DURSUN E., YıLMAZER S.

BİOCHEMISTRY ANALYTICAL BIOCHEMISTRY , cilt.5, sa.3, ss.48, 2016 (Hakemli Dergi)

9. BDNF, TNF?, HSP90, CFH and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment

YILMAZER S., GEZEN AK D., DURSUN E.

JOURNAL OF ALZHEIMERS DISEASE , cilt.4, ss.11-23, 2013 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 40

1. Reduced cerebrospinal fluid levels of the PCK2 protein in patients with Alzheimer's disease

Ilhan N., Ildiz S., Sahin E., SORDU DELİBALTA P., SAMANCI B., ALAYLIOĞLU M., et al.

57th Conference of the European-Society-of-Human-Genetics (ESHG), Berlin, Almanya, 1 - 04 Haziran 2024, cilt.32, ss.1502-1503, (Özet Bildiri)

2. possible diagnostic biomarkers in the differential diagnosis of autoimmune demyelinating central nervous system diseases: sorcin and clic1

KARAASLAN Z., Yediel B. S., ŞANLI E., YÜCEER KORKMAZ H., DURSUN E., GEZEN AK D., et al.

9th Joint ECTRIMS-ACTRIMS meeting, Milan, İtalya, 11 - 13 Ekim 2023, ss.574-575, (Özet Bildiri)

3. Cognitive involvement in ATTR amyloidosis (TTR-FAP)

DURMUŞ TEKÇE H., ÇAKAR A., Demirci H., Alaylioglu M., GEZEN AK D., DURSUN E., et al.

Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK, 01 Ocak 2020, cilt.25, ss.527, (Özet Bildiri)

4. MATERNAL FOKL VDR POLYMORPHISM IS A DETERMINANT OF BOTH MATERNAL AND NEONATAL 25(OH)D STATUS AT BIRTH: A VALIDATION COHORT FROM NORTHERN GREECE

Karras S., Koufakis T., Goulis D., Annweiler C., Dursun E., Gezen-Ak D., et al.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO), Paris, Fransa, 4 - 07 Nisan 2019, cilt.30, (Özet Bildiri)

5. DETERMINANTS OF NEONATAL 25(OH)D STATUS IN A GREEK POPULATION COHORT

Karras S., Koufakis T., Goulis D., Annweiler C., Dursun E., Gezen-Ak D., et al.

World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO), Paris, Fransa, 4 - 07 Nisan 2019, cilt.30, (Özet Bildiri)

6. Novel anti-neuronal antibodies in idiopathic intracranial hypertension patients

Tuzun E., Altiokka-Uzun G., Erdag E., Gezen-Ak D., Dursun E., Kucukali C. I., et al.

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

7. OKA induced tau hyperphosphorylation decrease BDNF protein levels in primary cortical neuron cultures

Atasoy İ., YILMAZER S., DURSUN E., METİN D., ÖZTÜRK SEZGİN M., GEZEN AK D.

EMC2016 (European Microscopy Congress 2016), Lyon, Fransa, 28 Ağustos - 02 Eylül 2016, ss.0-53, (Tam Metin Bildiri)

8. The effect of tau hyperphosphorylation on Pin1 expression in primary cortical neurons.

Metin D., GEZEN AK D., DURSUN E., Atasoy İ., YILMAZER S., Karabay Korknmaz A., et al.

EMC2016 (European Microscopy Congress 2016), Lyon, Fransa, 28 Ağustos - 02 Eylül 2016, (Tam Metin Bildiri)

9. Investigation of the effect of anacardic acid on ICAM-1, VCAM-1 and NF-?B in human saphenous vein graft endothelial culture induced with TNF-alpha

Önal B., Akkan A. G., Gezen Ak D., Demir B., ÖZYAZGAN S.

7th European Congress of Pharmacology, İstanbul, Türkiye, 26 - 30 Haziran 2016, ss.312, (Tam Metin Bildiri)

10. Clusterin polimorfizmleri ile geç başlangıçlı Alzheimer hastalığı arasındaki ilişki.

Alaylıoğlu M., GEZEN AK D., BİLGİÇ B., Eker E., DURSUN E., Gürvit H., et al.

14. Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Türkiye, 27 - 30 Ekim 2015, cilt.1, sa.1, ss.1, (Özet Bildiri)

11. lzheimer ve Parkinson tipi nörodejenerasyonda bir sekosteroid hormon: vitamin D.

GEZEN AK D.

14.Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Türkiye, 27 - 30 Ekim 2015, cilt.1, sa.1, ss.1, (Özet Bildiri)

12. Kültürdeki nöronlarda OKA ile indüklenen Tau hiperfosforilasyonunun BDNF proteini üzerindeki etkilerinin immünfloresan ve ELISA yöntemleriyle incelenmesi.

ATASOY I. L., DURSUN E., GEZEN AK D., Metin D., ÖZTÜRK SEZGİN M., YILMAZER S.

14.Tıbbi Biyoloji ve Genetik Kongresi, Muğla, Türkiye, 27 - 30 Ekim 2015, cilt.1, sa.1, ss.1, (Özet Bildiri)

13. Compromised Regulation of Serum Cytokine Levels and BDNF Due to Low Levels of Vitamin D in Patients with Early or Late Onset Alzheimer’s Disease or Parkinson’s Disease.

GEZEN AK D., BİLGİÇ B., HANAĞASI H. A., ERTAN F. S., LOHMANN E., ATASOY I. L., et al.

Alzheimer’s Association International Conference (AAIC 2015), 17-23 July, 2015 Washington, USA, Washington, Amerika Birleşik Devletleri, 17 - 23 Temmuz 2015, ss.1-2, (Özet Bildiri)

14. Association Between Clusterin Polymorphisms and Alzheimer’s Disease.

Alaylıoğlu M., GEZEN AK D., DURSUN E., HANAĞASI H. A., BİLGİÇ B., GÜRVİT İ. H., et al.

Alzheimer’s Association International Conference (AAIC 2015), 17-23 July, 2015 Washington, USA, Washington, Amerika Birleşik Devletleri, 17 - 23 Temmuz 2015, ss.1, (Tam Metin Bildiri)

15. Vitamin D Dependent Regulation of Gamma Secretase Complex.

DURSUN E., ATASOY I. L., Alaylıoğlu M., YILMAZER S., GEZEN AK D.

Alzheimer’s Association International Conference (AAIC 2015), 17-23 July, 2015 Washington, USA, Washington, Amerika Birleşik Devletleri, 17 - 23 Temmuz 2015, ss.1-2, (Tam Metin Bildiri)

16. The effect of vitamin D treatment on GLIA derived neurotrophic factor in cortical neurons

Yilmazer S., Ulutin T., Dursun E., Gezen-Ak D.

16th Annual Conference of the International-Society-for-Bipolar-Disorders, Seoul, Güney Kore, 18 - 21 Mart 2014, cilt.16, ss.87-88, (Özet Bildiri)

17. Polymorphisms in Her2/Neu and MMP1 genes and associations with breast cancer risk

Öztürk M., Kaya-Dagistanli F., Dursun E., Gezen-Ak D., Cagatay P., Ilvan S., et al.

38th Congress of the Federation-of-European-Biochemical-Societies (FEBS), Saint Peter, Guernsey Ve Alderney, 6 - 11 Temmuz 2013, cilt.280, ss.74, (Özet Bildiri) Sürdürülebilir Kalkınma

18. Association of caspase-9 promoter region polymorphisms and breast cancer

Ozturk M., Metin D., Kaya-Dagistanli F., Gezen-Ak D., Dursun E., Ilvan S., et al.

38th Congress of the Federation-of-European-Biochemical-Societies (FEBS), Saint Peter, Guernsey Ve Alderney, 6 - 11 Temmuz 2013, ss.76, (Özet Bildiri)

19. Serum complement factor H levels in late onset Alzheimer's disease

Yilmazer S., Gezen-Ak D., Dursun E., Hanagasi H., Bilgic B., Lohman E., et al.

38th Congress of the Federation-of-European-Biochemical-Societies (FEBS), Saint Peter, Guernsey Ve Alderney, 6 - 11 Temmuz 2013, cilt.280, ss.430, (Özet Bildiri)